A dual GIP/GLP-1 receptor agonist studied in the SURMOUNT and SURPASS clinical trial programs. It activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, producing differentiated metabolic outcomes compared to GLP-1–only agonists.
Code SOL saves 10% at Live Alpha Labs.